253 related articles for article (PubMed ID: 30964081)
1. Dendritic cell engineering for selective targeting of female reproductive tract cancers.
Bhargava A; Srivastava RK; Mishra DK; Tiwari RR; Sharma RS; Mishra PK
Indian J Med Res; 2018 Dec; 148(Suppl):S50-S63. PubMed ID: 30964081
[TBL] [Abstract][Full Text] [Related]
2. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine.
Bhargava A; Bunkar N; Khare NK; Mishra D; Mishra PK
Nanomedicine (Lond); 2014 Jul; 9(14):2187-202. PubMed ID: 25405796
[TBL] [Abstract][Full Text] [Related]
3. Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.
Bhargava A; Mishra D; Banerjee S; Mishra PK
J Drug Target; 2013 Feb; 21(2):126-36. PubMed ID: 23061479
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
Bhargava A; Mishra D; Banerjee S; Mishra PK
Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells as cancer therapeutics.
Bryant CE; Sutherland S; Kong B; Papadimitrious MS; Fromm PD; Hart DNJ
Semin Cell Dev Biol; 2019 Feb; 86():77-88. PubMed ID: 29454038
[TBL] [Abstract][Full Text] [Related]
6. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer?
Chen W; Rains N; Young D; Stubbs RS
J Gastroenterol Hepatol; 2000 Jul; 15(7):698-705. PubMed ID: 10937673
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of lipid based nano-carrier systems for dendritic cell based targeting of tumor re-initiating cells in gynecological cancers.
Bhargava A; Mishra DK; Jain SK; Srivastava RK; Lohiya NK; Mishra PK
Mol Immunol; 2016 Nov; 79():98-112. PubMed ID: 27764711
[TBL] [Abstract][Full Text] [Related]
9. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.
Huang FP; Chen YX; To CK
Eur J Immunol; 2011 Jan; 41(1):18-25. PubMed ID: 21182072
[TBL] [Abstract][Full Text] [Related]
10. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
11. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo.
Rossowska J; Pajtasz-Piasecka E; Szyda A; Krawczenko A; Zietara N; Dus D
Oncol Rep; 2009 Jun; 21(6):1539-49. PubMed ID: 19424635
[TBL] [Abstract][Full Text] [Related]
12. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
Sioud M; Saebøe-Larssen S; Hetland TE; Kaern J; Mobergslien A; Kvalheim G
Int J Oncol; 2013 Jul; 43(1):280-8. PubMed ID: 23620105
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells and their potential therapeutic role in haematological malignancy.
Kaminski ER; Goddard RV; Prentice AG
Leuk Lymphoma; 2003 Oct; 44(10):1657-66. PubMed ID: 14692516
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic dendritic cell-based cancer vaccines: the state of the art.
Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE
Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347
[TBL] [Abstract][Full Text] [Related]
15. Immune cell engineering: opportunities in lung cancer therapeutics.
Bhargava A; Mishra DK; Tiwari R; Lohiya NK; Goryacheva IY; Mishra PK
Drug Deliv Transl Res; 2020 Oct; 10(5):1203-1227. PubMed ID: 32172351
[TBL] [Abstract][Full Text] [Related]
16. Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang CL; Balint K; Coukos G; Kandalaft LE
Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
[TBL] [Abstract][Full Text] [Related]
17. Harnessing dendritic cells in cancer.
Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
[TBL] [Abstract][Full Text] [Related]
18. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
20. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
